Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent?
The atopic dermatitis market is crowded. Dupixent, from Regeneron and Sanofi, may be king of the arsenal of therapies to combat eczema — but various drugmakers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
